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Abstract Phosphatidic acid (PA) is an important second mes-
senger produced by the activation of numerous cell surface re-
ceptors. Recent data have suggested that PA regulates multiple
cellular processes. This review addresses primarily the role of
PA in the regulation of the Erk1/2 cascade pathway. A model
for the regulation of Erk1/2 phosphorylation by cell surface
receptors is presented. According to this model, agonists stim-
ulate the binding of GTP to Ras and the activation of phospho-
lipase D to generate phosphatidic acid. PA promotes the binding
of cRaf-1 kinase to the membrane, where it interacts with
Ras.GTP and other regulatory components of the pathway.
Ras^Raf complexes remain bound to the surface of endosomes,
where sca¡olding complexes involving Ras, cRaf-1, MEK and
Erk are formed. Complete activation and coupling of the cas-
cade requires endocytosis, a process that is also modulated by
PA.
- 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Phosphatidic acid as a second messenger
Phosphatidic acid (PA) is an important metabolite involved
in phospholipid biosynthesis and membrane remodeling.
However, recent data have suggested that PA may play a
crucial role in the regulation of several important biological
events. For instance, PA has been implicated in the regulation
of protein phosphorylation [1^8], in the activation of oxida-
tive processes [9^11], and in the modulation of membrane
tra⁄c [12^14]. Many of these processes are mediated by a
previously unsuspected role of PA: the binding of PA in a
highly selective and speci¢c manner. Thus, PA appears to
function in a manner similar to many other lipid second mes-
sengers: by promoting the binding of selected targets to spe-
ci¢c regions of the cell membrane.
The direct interaction of PA with cell proteins has been
demonstrated in a small group of proteins. Thus, the interac-
tions of PA with the protein kinase cRaf-1 have been mapped
to a 35 amino acid stretch in the CR3 domain of the protein
[2,5], and the binding of mTOR seems to involve R2109 near
the rapamycin-binding domain of the protein [1]. Likewise,
the binding of PA to the cAMP-speci¢c phosphodiesterase
PDE4D3 seems to be mediated by amino acids 31^59, located
within the regulatory domain of the protein [15], and the PA
binds to residues contained within the 41 C-terminal amino
acids of the tyrosine protein phosphatase SHP-1 [16]. Fig. 1
shows the sequences of the putative binding sites of Raf,
KSR, mTOR, PDE4D3 and SHP-1.
Examination of these putative PA-binding domains does
not reveal great similarity among these sequences, except for
the fact that they all contain at least one polybasic motif. In
the case of cRaf-1 and mTOR, this polybasic motif is £anked
by one or two hydrophobic stretches. The PA-binding region
of SHP-1 is located in the C-terminal end of the protein, in a
long hydrophilic stretch that contains 15 basic and six acidic
residues. Finally, the putative PA-binding region of PDE4D3
is characterized by two histidine-rich stretches. The identi¢ca-
tion of consensus PA-interacting motifs does not appear fea-
sible at this time given the small number of putative target
sequences. More recent work has demonstrated the existence
of two PA-binding sites within the PX domain of p47phox (L.
McPhail, personal communication). Although no information
on the actual PA-binding sites is available at this time, the PX
domain of p47phox contains one RR pair at the end of a
hydrophobic stretch that bears similarity to the PA-binding
regions of Raf-1 and mTOR, suggesting this as a common
motif for at least a sub-class of PA-binding proteins.
However, there is little doubt that PA plays a signi¢cant
role in the regulation of the function of these proteins. The
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Fig. 1. The putative PA-binding domains of Raf-1, A-Raf, B-Raf,
KSR, mTOR, SHP-1 and PDE4D3. Raf-1, A-Raf and B-Raf are
protein kinases of the Raf family. KSR is the kinase suppressor of
Ras, a putative sca¡olding protein. mTOR (target of rapamycin) is
a protein kinase related to the PI3 kinase superfamily. SHP-1 (or
PTP1C) is a protein tyrosine phosphatase. PDE4D3 is one of the
isoforms of cAMP-speci¢c phosphodiesterase.
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binding of PA to SHP-1, for instance, activates the phospha-
tase in vitro [16], and the data clearly indicate that the inter-
actions with PA are essential for the recruitment of cRaf-1 to
membranes [5].
2. Receptor-mediated regulation of PA production
PA can be generated by several cellular processes: (a) the
hydrolysis of phosphatidylcholine (PC) by phospholipase D
(PLD); (b) the phosphorylation of diacylglycerol (DAG) by
DAG kinase; and (c) the acylation of lyso-PA by lyso-PA acyl
transferases. All of these processes are regulated at some level
by extracellular signals. The regulation of PA levels by mod-
ulation of the activity of PLD and by the regulation of DAG
kinase has been reviewed extensively [17^19].
PLD activity is stimulated by many cell surface receptors,
including receptor tyrosine kinases, G protein-coupled recep-
tors and cytokine receptors (see the review by Exton [19]).
Mammalian cells express two isoforms of PLD, PLD1 and
PLD2. Overexpression of either isoform increases agonist-de-
pendent PLD responses in model systems. However, only the
overexpression of a catalytically inactive mutant of PLD2
(K758R-PLD2) appears to inhibit PLD.5 activation by insulin
or PDGF in HIRcB ¢broblasts [20,21], or by angiotensin II
and PDGF in vascular smooth muscle cells [22,23]. In these
systems, the overexpression of the catalytically inactive
K898R-PLD1 was without e¡ect.
These data suggest that PLD2 is the main target for recep-
tor-dependent PLD activation. The dominant negative e¡ects
of K758R-PLD2 have provided one of the few tools available
to study the role of PA and PLD activation in cellular pro-
cesses. In fact, the only pharmacological inhibitors of PLD
available to date are short-chain primary alcohols, which ac-
tually function as alternative substrates to water in the trans-
phosphatidylation reaction catalyzed by PLD. Therefore,
since the inhibition of PA formation by primary alcohols is
accompanied by the formation of phosphatidylalcohols, the
data obtained using these inhibitors are always di⁄cult to
interpret.
3. The regulation of protein phosphorylation by PA
Several studies have suggested that PA may regulate speci¢c
kinase cascades. For instance, recent work on the mTOR
signaling cascade has shown that 1-butanol, but not 2-buta-
nol, inhibits serum-stimulated activation of S6 kinase, one of
the main targets of mTOR [1]. Likewise, treatment with etha-
nol inhibits phorbol ester-induced translocation of cRaf-1 to
membranes [2]. In vitro studies have demonstrated that there
are at least two-protein kinase activities regulated by PA in
neutrophils. The protein tyrosine kinase Fgr [7] and a novel
protein kinase have been implicated in these activities [4].
Likewise, the PKC isoform PKC-j appear to be activated
by direct interactions with PA [3]. However, the best charac-
terized functional role of PA in the regulation of protein phos-
phorylation cascades remains the regulation of the Ras/Raf/
MEK/Erk cascade.
The protein kinase cRaf-1 is one of the main targets of the
small GTPase Ras. Ras is a membrane-bound protein; there-
fore, it has long been argued that cRaf-1 activation requires
its translocation to the membrane. According to the current
models of cRaf-1 activation, Ras^Raf interactions play a cen-
tral role in the translocation of cRaf-1 to the membrane.
However, the binding of activated Ras.GTP to cRaf-1 is
only part of the story. cRaf-1 is phosphorylated in serine,
threonine and tyrosine residues by speci¢c enzymes, and these
phosphorylation reactions appear to be essential for the acti-
vation of the kinase (see [24] for a review). The idea that PA is
a regulator of the Erk phosphorylation cascade was ¢rst pro-
posed by Ghosh et al. in 1996 [2]. Ghosh et al. reasoned that,
since cRaf-1 must interact with the membrane in order to be
activated, then the interaction with speci¢c phospholipids may
contribute signi¢cantly to the stabilization of cRaf-1^mem-
brane complexes [2]. They went on to show that cRaf-1 inter-
acts with phosphatidylserine in a highly selective manner
[2,25]. However, during these studies, a second lipid-binding
site, speci¢c for PA, was detected in the CR3 domain of
cRaf-1 [2]. Mutational analysis determined that the PA-bind-
ing site was contained within a 35 amino acid fragment within
the CR3 region of cRaf-1, downstream of the ATP-binding
site of the kinase [2].
The relative importance of Ras and PA binding in the
translocation of cRaf-1 to membranes was studied in detail
more recently. Rizzo et al. demonstrated that PA binding
rather than Ras^Raf interactions drives the translocation of
cRaf-1 to the membrane [5]. This was done by a combination
of studies in which PA production or the binding of cRaf-1 to
PA were impaired by molecular techniques. In summary, these
studies showed that the blockade of PA production by expres-
sion of a dominant negative PLD2 mutant inhibits insulin-
dependent translocation of cRaf-1 to the membrane and
Erk1/2 phosphorylation, and that addition of PA reverted
the inhibitory e¡ects of the dominant negative PLD2 [6].
PA promoted the translocation of cRaf-1 to membranes,
but failed to stimulate Raf kinase activity in vitro [6]. Fur-
thermore, the mutation of a single residue of the polybasic
motif of cRaf-1 within the putative PA-binding domain
(R398A) was su⁄cient to reduce the a⁄nity of the protein
for PA, to impair the binding of the mutant protein to mem-
branes, and to interfere with insulin-dependent phosphoryla-
tion of Erk1/2 [5]. In fact, the e¡ects of this mutation of the
PA-binding site on the translocation of cRaf-1 to membranes
were signi¢cantly more dramatic than those of a mutation of
a speci¢c residue in the Ras-binding domain of cRaf-1 that
signi¢cantly reduced Ras^Raf interactions (R89L). Finally,
the overexpression of a construct containing the putative
PA-binding domain of cRaf-1 fused to Aequorea victoria
green £uorescent protein blocked insulin-dependent Erk1/2
phosphorylation in HIRcB ¢broblasts [5]. More recently, de-
tailed in vitro studies have con¢rmed that speci¢c lipid inter-
actions rather than the binding of Ras drive the binding of
B- and cRaf-1 to membranes [26].
These studies therefore suggest that PA production plays a
central role in the activation of the Erk pathway. The model
that arises from these observations states that the transloca-
tion of cRaf-1 to the membrane is primarily driven by the
binding of PA. Further studies in other model systems have
con¢rmed at least in part the validity of this model. For in-
stance, the expression of K758R-PLD2 in vascular smooth
muscle cell lines and primary cultures has been shown to in-
hibit the production of PA by angiotensin II and PDGF
[23,22]. This inhibition was accompanied by a decrease in
agonist-induced MEK and Erk phosphorylation, and the ef-
fects of K758R-PLD2 were reversed by the addition of PA.
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4. PA, endocytosis and sca¡olding
Some more recent work has suggested that the binding of
cRaf-1 to the plasma membrane is insu⁄cient for the activa-
tion of the Erk1/2 cascade. In fact, the data indicate that
endocytosis is essential in the mechanism of regulation of
Erk1/2 phosphorylation by cell surface receptors. The evi-
dence supporting this view arises from several sources. For
instance, dynamin-dominant negative mutants block endocy-
tosis and uncouple the Erk1/2 phosphorylation pathway [27^
29]. Likewise, the blockade of endocytosis with inhibitors such
as cytochalasin D also results in the inhibition of receptor-
dependent Erk1/2 phosphorylation. More recent work has
shown that treatment with cyclodextrin, a reagent that scav-
enges cholesterol from the plasma membrane, blocks the traf-
¢c of Ras and cRaf-1 and the phosphorylation of MEK and
Erk1/2 without a¡ecting the translocation of cRaf-1 to the
membrane and the subsequent activation of its kinase activity
[30].
Recent work has established a direct link between the gen-
eration of PA and the regulation of endocytosis. PA and other
acidic phospholipids facilitate the binding of dynamin to
membranes [31]. However, the role of PA in vesicle tra⁄c
appears to be much more general than the modulation of
endocytosis. PA has also been shown to facilitate the binding
of AP-2 and clathrin coats to lysosomal membranes [32]. En-
dophilin A1, a protein that plays a very important role in the
recycling of synaptic vesicles, has been shown to have a lyso-
PA acyl transferase activity [33]. PA also seems to play a
major role in Golgi tra⁄c, whether it is produced by PLD
[13,34] or by acylation of lyso-PA [35]. In general, PA appears
to facilitate the ¢ssion of vesicles. This function of PA appears
to be a consequence of the selective interaction of the lipid
with speci¢c target proteins, but given the peculiar structure
of PA molecules (a lipid with a small head group and two
bulky fatty acid chains attached to the glycerol), it has been
proposed that PA may facilitate the formation of local regions
of negative curvature on cell membranes [36,37].
Independently of the speci¢c details of the phenomenon,
some recent work has shown that PA is enriched in endo-
somes [5]. Ghosh et al. determined the stoichiometry of PA
binding to cRaf-1 to be between three and six [2]. If this
stoichiometry is correct, simple calculations show that a
two-fold enrichment in the mol fraction of PA on endosomes
Fig. 2. A model for the role of phosphatidic acid in the regulation of the Erk1/2 cascade. Cell surface receptors activate PLD and Ras via inde-
pendent, parallel mechanisms. PA promotes the binding of cRaf-1 to the plasma membrane. PA also facilitates the formation of endocytic
vesicles. Ras^Raf complexes and speci¢c sca¡olding proteins that carry MEK and Erk1/2 accumulate on the surface of these endosomes. MEK
and Erk1/2 phosphorylation occurs on the surface of these vesicles.
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would lead to an eight- to 64-fold increase in the apparent
a⁄nity of cRaf-1 for the surface of the endosome, therefore
explaining why shortly after agonist stimulation most of
cRaf-1 is found bound to the surface of endosomes [5]. Inter-
estingly, the protein KSR (Kinase Suppressor of Ras), re-
cently shown to be a sca¡olding protein that binds MEK
and Erk1/2 [38,39], contains a fragment with greater than
90% homology to the PA-binding region of cRaf-1. We pro-
pose, therefore, that PA plays a central role in the accumu-
lation of signaling and sca¡olding proteins on the surface of
endosomes, and that such a role is essential for the coupling
of the Erk1/2 kinase cascades.
A working model based on these ideas is depicted in Fig. 2.
In this model, cell surface receptors activate two signaling
pathways, one leading to the activation of Ras, and the sec-
ond to the activation of ARF or Rho family proteins. Acti-
vated ARF and/or Rho causes the activation of PLD2 and the
local accumulation of PA. PA induces the recruitment of
cRaf-1 to the plasma membrane, where it interacts with Ras
and becomes activated. PA also catalyzes the formation of
endocytic vesicles. Ras^Raf complexes tra⁄c with these endo-
somes. Sca¡olding proteins, such as KSR, are then recruited
to the endosome by direct interactions with PA or other reg-
ulatory molecules. These sca¡olding proteins carry with them
MEK and Erk, therefore catalyzing the coupling of the phos-
phorylation cascade. This model is consistent with our obser-
vations and those of many other laboratories. Further testing
will be required to con¢rm these ideas.
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